Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P47895
UPID:
AL1A3_HUMAN
Alternative names:
Aldehyde dehydrogenase 6; Aldehyde dehydrogenase family 1 member A3
Alternative UPACC:
P47895; Q6NT64
Background:
Retinaldehyde dehydrogenase 3, also known as Aldehyde dehydrogenase 6 and Aldehyde dehydrogenase family 1 member A3, plays a pivotal role in the NAD-dependent oxidation of aldehyde substrates. This includes the conversion of all-trans-retinal and all-trans-13,14-dihydroretinal into their corresponding carboxylic acids, crucial for retinoate biosynthesis in embryonic ocular and nasal regions.
Therapeutic significance:
The protein is directly linked to Microphthalmia, isolated, 8, a disorder affecting eye formation. Understanding the role of Retinaldehyde dehydrogenase 3 could open doors to potential therapeutic strategies for ocular developmental disorders.